Preclinical data highlighting ERNA-101’s potential to activate the ovarian cancer tumor microenvironment and enhance checkpoint blockade will be presented October 6, 2026, at MD Anderson Cancer Center ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results